Demographic and clinical characteristics of patients with MS with and without comorbiditiesa
| Total Patients with MS (N = 815) | Patients with MS with Comorbidities (n = 241) | Patients with MS without Comorbidities (n = 574) | P Valueb | |
|---|---|---|---|---|
| Females (No.) (%) | 626 (76.8) | 201 (83.4) | 425 (74.0) | .300 |
| Age (yr) (mean) (SD) | 45.7 (10.3) | 46.3 (10.4) | 45 (10.2) | .082 |
| Disease duration (yr) (mean) (SD) | 13.1 (9.4) | 13.3 (10) | 12.8 (8.8) | .452 |
| EDSS (median) (IQR) | 2.5 (1.5–6.0) | 2.5 (1.5–5.5) | 2.5 (2.0–6.0) | .732 |
| MS subtype (No.) (%) | ||||
| RR | 554 (67.9) | 157 (65.1) | 397 (69.2) | .120 |
| SP | 227 (27.9) | 77 (32.0) | 150 (26.1) | |
| PP | 34 (4.2) | 7 (2.9) | 27 (4.7) | |
| DMT use (No.) (%) | 598 (73.4) | 175 (72.6) | 423 (73.7) | .900 |
| DMT months (mean) (SD) | 48.9 (35.2) | 48.8 (35.2) | 49 (39.2) | .942 |
Note:—RR indicates relapsing-remitting; SP, secondary-progressive; PP, primary-progressive; DMT, disease-modifying therapy; IQR, interquartile range.
↵a Demographic and clinical characteristics were tested using the χ2, Student t, and Mann-Whitney rank sum tests.
↵b P values refer to analyses between patients with MS with and without comorbidities.